Detalles de la búsqueda
1.
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Ann Hematol
; 103(1): 259-268, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37861736
2.
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2499-2512, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37041225
3.
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Cytotherapy
; 25(9): 986-992, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055322
4.
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Eur J Nucl Med Mol Imaging
; 50(5): 1406-1413, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36513818
5.
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Am J Hematol
; 98(11): 1699-1710, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37584447
6.
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Haematologica
; 107(9): 2096-2107, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172565
7.
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.
Blood
; 140(20): 2175-2179, 2022 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35776908
8.
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2513-2514, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154851
9.
Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.
Br J Haematol
; 179(3): 480-487, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28832948
10.
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Blood Adv
; 8(8): 1857-1868, 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38181508
11.
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria.
Cancer Imaging
; 23(1): 44, 2023 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37189191
12.
Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy.
Cancer Immunol Res
; 11(6): 707-719, 2023 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37040425
13.
Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity.
Neurooncol Adv
; 5(1): vdad135, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38024243
14.
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.
Blood Adv
; 7(11): 2436-2448, 2023 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36607834
15.
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL.
Hemasphere
; 7(4): e858, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37038465
16.
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Sci Adv
; 9(38): eadg3919, 2023 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738350
17.
Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment.
Blood Adv
; 6(10): 3022-3026, 2022 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35042236
18.
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Neurology
; 98(21): 884-889, 2022 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35351785
19.
Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment.
Front Oncol
; 12: 974029, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36158658
20.
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Front Immunol
; 12: 608625, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33790890